Table 4. Oncologic efficacy of ALPPS.
| Study | Number of R0 resections (%) | OS at 1 year (%) | OS at 3 years (%) | Median survival, (months) | DFS at 1 year (%) | DFS at 3 years (%) | Median DFS (months) | Critical oncological discussion points by authors |
|---|---|---|---|---|---|---|---|---|
| Albert Chan | 100 | 84.7 | 60.2 | NA | 63.2 | 34.9 | NA | ALPPS same as PVE but higher resection rate |
| Zhang Wang | 100 | 64.2 | 60.2 | NA | 47.6 | 43.6 | NA | ALPPS same as one stage RH, better than TACE |
| Daryl Chia | 100 | NA | NA | NA | NA | NA | NA | ALPPS for HCC with decreased liver remnant growth |
| Qiang Wang | 100 | NA | NA | NA | NA | NA | NA | RALPPS is at the cost of a longer interval time |
| Xiujun Cai | 100 | 50 | 28.6 | NA | NA | NA | NA | FLR/SLV <30% is not recommended for ALPPS in HCC |
| Chang Gung | NA | NA | NA | NA | NA | NA | NA | ALPPS procedure can be performed safely in a highly selected group of primary HCC |
| Vennarecci | 100 | NA | NA | NA | NA | NA | Na | ALPPS induced FLR growth in HCC same as non-HCC |
| D’Haese | NA | NA | NA | NA | NA | NA | 12 | ALPPS for HCC should be performed only for younger than 60 years with low-grade fibrosis |
| Björnsso | NA | NA | NA | NA | NA | NA | NA | ALPPS may be applied in selected patients with HCC |
ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; OS, overall survival; DFS, disease-free survival; NA, not available; PVE, portal vein embolization; RH, right hepatectomy; TACE, transcatheter arterial chemoembolization; HCC, hepatocellular carcinoma; RALPPS, radiofrequency-assisted ALPPS; FLR, future liver remnant; SLV, standard liver volume.